An Old Drug Tackles New Tricks: Ivermectin Treatment in Three Brazilian Towns: TrialSite News continues to develop a global network of individuals, from all walks of life, participating and sharing their experiences from around the world. They share a common bond: a dedication to health, community well-being and research, from randomized controlled trials to real world observations and case series observations, contributing important observations related to COVID-19. Alan Cannell is one of these individuals. Originally from the UK, but based in the southern part of Brazil for many years, Mr. Cannell, an engineer by training who has participated in major projects around the world, shares his research observations as to the use of Ivermectin in Brazil. As TrialSite recently discussed, some municipal health departments in Brazil have approved Ivermectin-based regimens targeting COVID-19. This is a similar pattern to observations in some other parts of South America. Ivermectin is not specifically approved for the COVID-19 indication at the national level. https://www.trialsitenews.com/an-old-drug-tackles-new-tricks-ivermectin-treatment-in-three-brazilian-towns/
Clinical Trials and Research News Weekly Roundup | Ivermectin Treatment in Three Brazilian Towns
Chinese Academy of Sciences Team’s FDA Approved Ceftazidime Represents Potential COVID-19 Treatment: Researchers from the Chinese Academy of Sciences uncovered an antibiotic approved for the treatment of pneumonia actually binds to the same receptors that SARS-CoV-2 itself attaches to in human cells. Called ceftazidime, the Chinese researchers suggest this drug could inhibit or even prevent COVID-19. Published recently in the preprint server bioRxiv, this work is not peer reviewed and hence cannot be considered authoritative. Nonetheless, the intriguing findings were derived from an intensive screening of over 3,500 FDA-approved drug targets as well as small molecules. https://www.trialsitenews.com/chinese-academy-of-sciences-teams-fda-approved-ceftazidime-represents-potential-covid-19-treatment/
University of Buffalo Prepares Melatonin Trial Targeting Mild to Moderate COVID-19: Could the natural sleep aid melatonin serve as a treatment for patients with mild and moderate COVID-19? Apparently, researchers at the University at Buffalo seek to find out, and the university Institutional Review Board granted approval to proceed. The U.S. Food and Drug Administration (FDA) already granted approval of the Investigational New Drug (IND) Application. https://www.trialsitenews.com/university-of-buffalo-prepares-melatonin-trial-targeting-mild-to-moderate-covid-19/
Russia Health Ministry Allows Use of Favipiravir for Outpatient COVID-19 Use: Back on June 1, TrialSite reported that Russian regulators approved a version of favipiravir known as Avifavir for hospitalized patients. Now the Russian Healthcare Ministry has approved the use of two favipiravir-based preparations for outpatient treatment for the SARS-CoV-2 indication. https://www.trialsitenews.com/russia-health-ministry-allows-use-of-favipiravir-for-outpatient-covid-19-use.
Source: TrialSite News